Effects of Salmeterol on Sleeping Oxygen Saturation in Chronic Obstructive Pulmonary Disease

Ryan, Suzanne; Doherty, Liam S.; Rock, Clare; Nolan, Geraldine; McNicholas, Walter T.

doi:10.1159/000235619

Cited by 56 publications

(48 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long-acting inhaled bronchodilators do not affect sleep quality [162,163]. Studies on indacaterol suggest that it reduces nocturnal awakenings due to dyspnoea, compared to placebo and comparators (tiotropium and salmeterol) [164,165].…”

Section: Impact Of Treatmentsmentioning

confidence: 99%

Comorbidities of COPD

Cavaillès¹,

Brinchault-Rabin²,

Dixmier³

et al. 2013

Eur Respir Rev

420

285

View full text Add to dashboard Cite

By 2020, chronic obstructive pulmonary disease (COPD) will be the third cause of mortality. Extrapulmonary comorbidities influence the prognosis of patients with COPD. Tobacco smoking is a common risk factor for many comorbidities, including coronary heart disease, heart failure and lung cancer. Comorbidities such as pulmonary artery disease and malnutrition are directly caused by COPD, whereas others, such as systemic venous thromboembolism, anxiety, depression, osteoporosis, obesity, metabolic syndrome, diabetes, sleep disturbance and anaemia, have no evident physiopathological relationship with COPD. The common ground between most of these extrapulmonary manifestations is chronic systemic inflammation.All of these diseases potentiate the morbidity of COPD, leading to increased hospitalisations and healthcare costs. They can frequently cause death, independently of respiratory failure. Comorbidities make the management of COPD difficult and need to be evaluated and treated adequately. @ERSpublications Extrapulmonary comorbidities are common in COPD and influence prognosis; we propose an exhaustive comorbidities review

show abstract

Section: Impact Of Treatmentsmentioning

confidence: 99%

Comorbidities of COPD

Cavaillès¹,

Brinchault-Rabin²,

Dixmier³

et al. 2013

Eur Respir Rev

420

285

View full text Add to dashboard Cite

show abstract

“…Several studies have investigated the effects of bronchodilator therapy [19,[64][65][66][67]. In a 4-week, double-blind study among 36 patients with moderate to severe COPD, treatment with ipratropium (given four times daily) led to an improvement in oxygen saturation and also in perceived sleep quality [66].…”

Section: Therapeutic Optionsmentioning

confidence: 99%

Night-time symptoms: a forgotten dimension of COPD

Agustí¹,

Hedner²,

Marı́n³

et al. 2011

Eur Respir Rev

206

189

View full text Add to dashboard Cite

Sleep quality is often poor in patients with chronic obstructive pulmonary disease (COPD), but these night-time symptoms are frequently unnoticed by physicians and/or not reported by patients themselves. Therefore, the prevalence and clinical impact of sleep disturbances and night-time symptoms in COPD is not well understood and has not been a clinical focus to date. To address this gap, an expert panel meeting was convened in Barcelona, Spain, in March 2011 to discuss the aetiology, evolution, burden, long-term clinical consequences and optimal management of night-time symptoms in COPD. The term ''night-time symptoms'' in COPD has not been distinctly defined in an objective sense but epidemiological data suggests that the prevalence of nocturnal symptoms and symptomatic sleep disturbance may exceed 75% in patients with COPD. The panel concluded that night-time symptoms in COPD are prevalent and bothersome; that their cause(s) are multiple and include demographic factors, such as age and obesity, pharmacotherapy, disease-specific symptoms and the presence of comorbid sleep disorders, and other medical conditions; and that potential long-term consequences can include lung function changes, increased exacerbation frequency, emergence or worsening of cardiovascular disease, cognitive effects, depression, impaired quality of life and increased mortality. To date, few interventional studies have investigated them, but emerging data suggest that bronchodilator therapy can improve them if deployed appropriately. In summary, night-time symptoms in COPD warrant further clinical investigation with validated tools.

show abstract

“…Previous studies showed equivocal benefits of theophylline, inhaled bronchodilators, and supplemental oxygen on sleep quality. [10][11][12][13][14][15] Management should therefore not just concentrate on drug control of airway obstruction.…”

Section: Introductionmentioning

confidence: 99%

Pulmonary Rehabilitation Improves Subjective Sleep Quality in COPD

et al. 2014

View full text Add to dashboard Cite

After PR, the PSQI score decreased from 9.41 ؎ 4.33 to 7.82 ؎ 3.90 (P < .001). The number of subjects with a PSQI score > 5 also decreased (85.3-64.7%, P ‫؍‬ .006). There were significant improvements in HRQOL (SGRQ, P ‫؍‬ .003), exercise capacity (peak oxygen uptake, P < .001; and work rate, P < .001), dyspnea score (P < .001), and respiratory muscle strength (inspiratory muscle strength, P ‫؍‬ .005; and expiratory muscle strength, P ‫؍‬ .004) after PR. There were no significant changes in pulmonary function test results (FEV 1 , P ‫؍‬ .77; FVC, P ‫؍‬ .90; FEV 1 /FVC, P ‫؍‬ .90). CONCLUSIONS: PR results in significant improvement in sleep quality, along with concurrent improvements in HRQOL and exercise capacity. PR is an effective nonpharmacologic treatment to improve sleep quality in patients with COPD and should be part of their clinical management.

show abstract

Effects of Salmeterol on Sleeping Oxygen Saturation in Chronic Obstructive Pulmonary Disease

Cited by 56 publications

References 54 publications

Comorbidities of COPD

Comorbidities of COPD

Night-time symptoms: a forgotten dimension of COPD

Pulmonary Rehabilitation Improves Subjective Sleep Quality in COPD

Contact Info

Product

Resources

About